Statin myopathy: Incidence, risk factors, and pathophysiology

被引：67

作者：

Sewright K.A. ^{[1
]}

Clarkson P.M. ^{[1
]}

Thompson P.D. ^{[1
]}

机构：

[1] Department of Kinesiology, University of Massachusetts, Amherst, MA 01002

来源：

Current Atherosclerosis Reports | 2007年 / 9卷 / 5期

关键词：

Statin; Myopathy; Statin Therapy; Statin Treatment; Statin Drug;

D O I：

10.1007/s11883-007-0050-3

中图分类号：

学科分类号：

摘要：

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are generally well-tolerated lipid-lowering drugs However they are associated with myopathy, and incidence rates of muscle-related complaints predicted from clinical trials may under-estimate rate of occurrence of these side effects in clinical practice. The development of a standardized system for description 1 a d documentation of statin-associated myopathy that includes the entire spectrum of muscle complaints wodld provide valuable data for researchers and clinicians eeking to better understand statin-induced muscle co~i plaints. Among the risk factors for myopathy are polypharmacy, high-dose statin treatment, aging, and diabetes. The etiology of statin-induced myopathy is not Well understood, but potenfial contributing mechanisms linclude decreases in mevalonate pathway products' mitochondrial dysfunction, alterations in gene expression related to apoptosis and protein degradation, and genetic predisposition. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：389 / 396

页数：7

共 46 条

[1]

Thompson P.D., Clarkson P., Karas R.H., Statin-associated myopathy, JAMA, 289, pp. 1681-1690, (2003)

[2]

Kashani A., Phillips C.O., Foody J.M., Et al., Risks associated with statin therapy: A systematic overview of randomized clinical trials, Circulation, 114, pp. 2788-2797, (2006)

[3]

Thavendiranathan P., Bagai A., Brookhart M.A., Choudhry N.K., Primary prevention of cardiovascular diseases with statin therapy: A meta-analysis of randomized controlled trials, Arch Intern Med, 166, pp. 2307-2313, (2006)

[4]

Maggini M., Raschetti R., Traversa G., Et al., The cerivastatin withdrawal crisis: A "post-mortem" analysis, Health Policy (Amsterdam), 69, pp. 151-157, (2004)

[5]

Pasternak R.C., Smith Jr S.C., Bairey-Merz C.N., Et al., ACC/AHA/NHLBI clinical advisory on the use and safety of statins, J Am Coll Cardiol, 40, pp. 567-572, (2002)

[6]

Yilmaz M.B., Pinar M., Naharci I., Et al., Being well-informed about statin is associated with continuous adherence and reaching targets, Cardiovasc Drugs Ther, 19, pp. 437-440, (2005)

[7]

Hansen K.E., Hildebrand J.P., Ferguson E.E., Stein J.H., Outcomes in 45 patients with statin-associated myopathy, Arch Intern Med, 165, pp. 2671-2676, (2005)

[8]

Sinzinger H., Wolfram R., Peskar B.A., Muscular side effects of statins, J Cardiovasc Pharmacol, 40, pp. 163-171, (2002)

[9]

Piercy M.A., Sramek J.J., Kurtz N.M., Cutler N.R., Placebo response in anxiety disorders, Ann Pharmacother, 30, pp. 1013-1019, (1996)

[10]

Thompson P.D., Clarkson P.M., Rosenson R.S., An assessment of statin safety by muscle experts, Am J Cardiol, 97, (2006)

← 1 2 3 4 5 →